Obstet Gynecol Sci.  2023 Jan;66(1):34-41. 10.5468/ogs.22241.

Micturition symptoms in gynecologic cancer patients receiving paclitaxel and platinum-based chemotherapy regimen: a prospective study

• Wudtisan J
• Suprasert P

• KMID: 2538345
• DOI: http://doi.org/10.5468/ogs.22241

Abstract

Objective
To evaluate the effect of paclitaxel and platinum-based chemotherapy (PT) on micturition symptoms.
Methods
All gynecologic cancer patients who were assigned to receive the PT regimen and understood the Thai language were invited to participate in this study. The exclusion criteria were as follows: abnormal urinary symptoms, retained urinary catheter or percutaneous nephrostomy, anticholinergic drug use, or scheduled to receive radiation therapy after the completion of chemotherapy. The participants were interviewed using three Thai validated questionnaires, the incontinence impact questionnaire-short form, urogenital distress inventory short form, and Sandvik score, on the day before receiving the first cycle of chemotherapy (pre-treatment), on the day before receiving the 4th cycle (mid-treatment), and 46 weeks after completing 69 cycles (post-treatment). The scores at the three time points were compared. Patients who received less than three cycles were not included in the analysis.
Results
One hundred and ten patients were included in this study. There were significant differences in the median questionnaire scores at the three time points for both carboplatin plus paclitaxel and cisplatin plus paclitaxel. However, when using a pairwise difference between the two treatment protocols, there were no significant changes in the score from pre-treatment to post-treatment.
Conclusion
The PT regimen has an impact on micturition symptoms during chemotherapy which recover after treatment completion.

Keyword

Urinary symptoms; Paclitaxel; Urinary incontinence

Reference

References

1. Chan JK, Chow S, Bhowmik S, Mann A, Kapp DS, Coleman RL. Metastatic gynecologic malignancies: advances in treatment and management. Clin Exp Metastasis. 2018; 35:521–33.

2. Staff NP, Fehrenbacher JC, Caillaud M, Damaj MI, Segal RA, Rieger S. Pathogenesis of paclitaxel-induced peripheral neuropathy: a current review of in vitro and in vivo findings using rodent and human model systems. Exp Neurol. 2020; 324:113121.

3. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol. 2006; 24:1633–42.

4. Santos NAGD, Ferreira RS, Santos ACD. Overview of cisplatin-induced neurotoxicity and ototoxicity, and the protective agents. Food Chem Toxicol. 2020; 136:111079.

5. Freeman R. Autonomic peripheral neuropathy. Neurol Clin. 2007; 25:277–301.

6. Cho OH, Yoo YS, Kim JC, Park RH, Hwang KH. Factors influencing lower urinary tract symptoms in advanced cancer patients with chemotherapy-induced peripheral neuropathy. Int Neurourol J. 2018; 22:192–9.

7. Strauchon CJ, Dengler KL, Gruber DD, Katebi Kashi P, Aungst MJ, Trikhacheva A, et al. Urinary symptoms in women receiving carboplatin/paclitaxel for treatment of gynecologic cancers. Int J Gynecol Cancer. 2020; 30:1418–23.

8. Weerasopone S, Santingamkul A. Validation of the Thai version of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6). Chula Med J. 2016; 60:389–98.

9. Sandvik H, Seim A, Vanvik A, Hunskaar S. A severity index for epidemiological surveys of female urinary incontinence: comparison with 48-hour pad-weighing tests. Neurourol Urodyn. 2000; 19:137–45.

10. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005; 5:13.

11. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007; 39:175–91.

12. Kim MK, Kim JH, Chae HD, Chung JH, Kim HJ, Lee SR, et al. Surgical outcomes of tension-free vaginal tape (TVT)-abbrevo® and TVT-obturator® for the treatment of stress urinary incontinence: a retrospective study. Obstet Gynecol Sci. 2021; 64:540–6.

13. Person F, Rinschen MM, Brix SR, Wulf S, Noriega MLM, Fehrle W, et al. Bevacizumab-associated glomerular microangiopathy. Mod Pathol. 2019; 32:684–700.

14. Gornstein E, Schwarz TL. The paradox of paclitaxel neurotoxicity: mechanisms and unanswered questions. Neuropharmacology. 2014; 76(Pt A):175–83.